Overview
This video features Dr. William Makis, a radiologist and oncologist, discussing the repurposing of antiparasitic drugs fenbendazole and mebendazole as potential cancer treatments. He explains that these drugs have demonstrated multiple biochemical mechanisms that may selectively target cancer cells, supported by extensive preclinical research. Despite promising case reports and some published clinical observations, the lack of large-scale clinical trials and regulatory approval limits their mainstream use.
Fenbendazole and Mebendazole in Cancer Treatment
Dr. Makis introduces fenbendazole, originally a veterinary antiparasitic, which gained attention after a terminal cancer patient, Joe Tippens, reportedly cured his stage 4 small cell lung cancer using this drug. Small cell lung cancer is typically highly aggressive with very poor survival rates. Tippens’ case, along with a published case series from Stanford University involving three patients who became cancer-free after fenbendazole treatment, illustrates potential anticancer effects. However, fenbendazole is not FDA-approved for human use.
Mebendazole, a structurally similar FDA-approved antiparasitic drug for humans, is undergoing multiple clinical trials investigating its anticancer properties. These trials include adult cancers such as colon and prostate cancer, as well as pediatric brain cancers. Mebendazole’s safety profile is well established, making it a more accessible candidate for repurposing in oncology.
Biochemical Mechanisms and Scientific Basis
Dr. Makis emphasizes that the anticancer effects of these drugs are grounded in well-understood biochemical pathways. For example, fenbendazole and mebendazole can block glucose transporters specifically on cancer cells, effectively starving them of energy without harming normal cells. This selective targeting is described as a "magic bullet" effect, where the drugs differentiate cancer cells from healthy ones.
He stresses that this is not speculative or fringe medicine but rather "hard science" based on hundreds of replicated preclinical studies. The drugs have multiple mechanisms of action, including promoting apoptosis (programmed cell death) and potentially reversing drug resistance in cancer cells. These effects have been observed in laboratory settings and animal models, providing a plausible scientific rationale for their anticancer activity.
Clinical Experience and Patient Outcomes
Dr. Makis shares his clinical experience with patients who have independently taken these repurposed drugs, often after exhausting standard cancer treatments. Many patients reported tumor shrinkage or stable disease, sometimes surprising their oncologists. He has also started a cancer coaching program to guide patients on the use of repurposed drugs, including dosing and side effect management.
He notes that repurposed drugs like fenbendazole and mebendazole may also have synergistic effects when combined with chemotherapy, immunotherapy, or radiation therapy, potentially enhancing treatment efficacy. This synergy is an area of ongoing interest but requires further research.
Challenges and Future Directions
Despite promising data, Dr. Makis highlights significant barriers to wider adoption of these drugs in oncology. The absence of financial incentives limits funding for large clinical trials, and regulatory agencies have not approved fenbendazole for human use. He advocates for more research to definitively answer questions about efficacy and safety.
Dr. Makis also discusses the ethical and practical considerations for patients with terminal cancers who have exhausted standard treatments. He supports the idea of "right to try" laws that would allow such patients access to experimental or repurposed drugs, emphasizing the importance of offering hope and options in dire situations.
Source Information
This content is based on a 16-minute YouTube video titled "Fen ben cancer and hard science" featuring Dr. William Makis, MD, a radiologist and oncologist. The video includes a detailed discussion of fenbendazole and mebendazole as repurposed antiparasitic drugs with potential anticancer effects. The transcript provides direct insights from Dr. Makis, including clinical anecdotes, scientific explanations, and commentary on the current state of research and regulatory challenges. No external sources or additional medical claims beyond the video transcript are included.
